Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Benzinga_recent_news04-14

The company focuses on developing and commercializing product candidates for retinal diseases. In February, data from the SOL-1 Phase 3 superiority trial fell short of investor expectations. The study...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment